BioLine Rx
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 79
- Market Cap
- $59.2M
- Website
- http://www.biolinerx.com
- Introduction
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumor...
Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 269
- Registration Number
- NCT01363349
- Locations
- 🇮🇳
RK Yadav Memorial Mental Health and De-addiction Hospital, Jaipur, India
🇮🇳Deva Mental Health Care, Varanasi, India
🇮🇳S.V.Medical College, Tirupati, India
A Study Intended to Evaluate Safety, Tolerability and Pharmacokinetics (PK) Parameters of BL-1021
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2014-03-13
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT01121380
- Locations
- 🇮🇱
Hadassah Clinical Research Center (HCRC), Jerusalem, Israel
Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020
- Conditions
- Interventions
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2010-06-29
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT00722176
- Locations
- 🇺🇸
University of California, Irvine, Irvine, California, United States
A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2010-06-29
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT00567710
- Locations
- 🇺🇸
Mary ann Knisevich, Irving, Texas, United States
Safety and Feasibility of the Injectable BL-1040 Implant
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT00557531
- Locations
- 🇩🇪
Heidelberg University MC, Heidelberg, Germany
Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder
- Conditions
- Interventions
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2009-07-21
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT00480571
- Locations
- 🇷🇴
Spitalul Clinic de Urgenţǎ Militar Central "Dr Carol Davila",, Bucharest, Str Mircea Vulcǎnescu 18, Romania
🇮🇱Dept. of Psychiatry, Sheba Medical Center, Tel Hashomer, Israel
A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer
- Conditions
- First Posted Date
- 2007-05-30
- Last Posted Date
- 2009-07-21
- Lead Sponsor
- BioLineRx, Ltd.
- Registration Number
- NCT00480246
- Locations
- 🇸🇪
Quintiles Phase I facility, Uppsala, Sweden
A Study of the Safety and Efficacy of Combination Therapy With Morphine, Phenylephrine and Sorbitol in Human Subjects
- Conditions
- Interventions
- First Posted Date
- 2006-09-12
- Last Posted Date
- 2008-04-15
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT00374881
- Locations
- 🇮🇱
Hadassah En Kerem Medical Centre, Jerusalem, Israel
🇮🇱Hadassah Hebrew University Medical Center, Department of Anesthesiology, Jerusalem, Israel